- ABC 7 News Ft. Dr. Steven Quay
- April 10th, 2020
Dr. Steven Quay, CEO of Atossa Therapeutics, proposes a combination of two FDA-approved drugs, heparin and N-acetylcysteine (NAC), to prevent COVID-19 patients from needing ventilators by disrupting the virus’s ability to enter the lungs.
Dubbed H-NAC, this drug combination aims to create a barrier against the virus, akin to peanut butter on car keys hindering access. Quay advocates for a clinical trial, hoping to start within 30 days, with the goal of enabling most COVID-19 patients to manage symptoms at home, reducing hospitalizations and associated risks.
The trial, named the COVID-19 Hope Trial, seeks to demonstrate the effectiveness of H-NAC administered through nebulizers, potentially revolutionizing treatment and alleviating strain on healthcare systems if successful.
